ConductScience.org, home

Paper42201625

Gut microbiota and cancer immunotherapy: from dysbiosis to personalized immune checkpoint blockade optimization.

Akram F and 3 others. Folia Microbiol (Praha), 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Gut microbiota and cancer immunotherapy: from dysbiosis to personalized immune checkpoint blockade optimization. Papers, record 42201625. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42201625

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Gut microbiota and cancer immunotherapy: from dysbiosis to personalized immune checkpoint blockade optimization.
PubMed
Journal
Folia Microbiol (Praha)
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-05-27
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Akram FFatimahttps://orcid.org/0000-0001-8438-706X
2Zainab SSalika
3Shabbir IIfrah
4Haq IUIkram Ul

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References200

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138319892Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.NEJM Evid2022https://conductscience.org/library/papers/38319892PubMed
228291584Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.Lancet Oncol2017https://conductscience.org/library/papers/28291584PubMed
332499569Host dysbiosis negatively impacts IL-9-producing T-cell differentiation and antitumour immunity.Br J Cancer2020https://conductscience.org/library/papers/32499569PubMed
428878676PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.Front Pharmacol2017https://conductscience.org/library/papers/28878676PubMed
533264544Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.N Engl J Med2020https://conductscience.org/library/papers/33264544PubMed
634239137Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.Nat Med2021https://conductscience.org/library/papers/34239137PubMed
737530622Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.Blood Adv2023https://conductscience.org/library/papers/37530622PubMed
828885881Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.N Engl J Med2017https://conductscience.org/library/papers/28885881PubMed
936460017
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Lancet Oncol2023https://conductscience.org/library/papers/36460017PubMed
1037361202The gut dysbiosis-cancer axis: illuminating novel insights and implications for clinical practice.Front Pharmacol2023https://conductscience.org/library/papers/37361202PubMed
1133485464First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.Lancet2021https://conductscience.org/library/papers/33485464PubMed
1215790844Host-bacterial mutualism in the human intestine.Science2005https://conductscience.org/library/papers/15790844PubMed
1335291651Commensal Microbiota and Cancer Immunotherapy: Harnessing Commensal Bacteria for Cancer Therapy.Immune Netw2022https://conductscience.org/library/papers/35291651PubMed
1432264958Tumor microenvironment complexity and therapeutic implications at a glance.Cell Commun Signal2020https://conductscience.org/library/papers/32264958PubMed
1534077643Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.N Engl J Med2021https://conductscience.org/library/papers/34077643PubMed
1629132146Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.Nature2017https://conductscience.org/library/papers/29132146PubMed
1728634130The inhibitory impacts of Lactobacillus rhamnosus GG-derived extracellular vesicles on the growth of hepatic cancer cells.Microb Pathog2017https://conductscience.org/library/papers/28634130PubMed
1823778791Compartmentalized and systemic control of tissue immunity by commensals.Nat Immunol2013https://conductscience.org/library/papers/23778791PubMed
1937028428Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment.Cell2023https://conductscience.org/library/papers/37028428PubMed
2037555952Microbiota as the unifying factor behind the hallmarks of cancer.J Cancer Res Clin Oncol2023https://conductscience.org/library/papers/37555952PubMed

See all 200 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42201625

GET https://conductscience.org/api/papers/v1/42201625/references?page=2